Other languages Johnson & Johnson Deutsche Boerse AG

Equities

Real-time Estimate Tradegate Other stock markets 07:51:11 03/07/2024 BST			5-day change	1st Jan Change
135.9 ^EUR	+0.01%		-1.43%	-4.45%

07-02	J&J: promising results in multiple myeloma	CF
07-02	Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	MT

Momentum Picks T3 2024: 5 valores para el verano	07-02
Momentum Picks Q3 2024: vijf aandelen voor de zomer	07-02
J&J : résultats prometteurs dans le myélome multiple	07-02
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	07-02
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	07-02
Momentum Picks Q3 2024: 5 azioni per l'estate	07-01
Momentum Picks T3 2024 : 5 actions pour l'été	07-01
En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...	07-01
Nouveau semestre, nouvel état d'esprit	07-01
Borsa di Italia: Un nuovo semestre, un nuovo umore	07-01
Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo	07-01
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	06-28
J&J Unit's Rybrevant Combo Gets EU Approval	06-28
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	06-28
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	06-28
Dealmakers optimistic on global M&A prospects despite sluggish growth	06-28
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	06-24
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21

No results for this search

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm